Aclaris Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2014 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Aclaris Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2014 to 2023.
  • Aclaris Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $3M, a 49.5% decline year-over-year.
  • Aclaris Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $9.26M, a 61.6% decline year-over-year.
  • Aclaris Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $20.5M, a 36.6% increase from 2022.
  • Aclaris Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $15M, a 6.96% increase from 2021.
  • Aclaris Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $14.1M, a 25.5% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $20.5M +$5.5M +36.6% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-27
2022 $15M +$979K +6.96% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-27
2021 $14.1M +$2.85M +25.5% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-27
2020 $11.2M -$4.88M -30.3% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-23
2019 $16.1M -$481K -2.9% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
2018 $16.6M +$3.98M +31.7% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 $12.6M +$6.48M +106% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-25
2016 $6.1M +$5.21M +585% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-18
2015 $891K +$864K +3200% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-12
2014 $27K Jan 1, 2014 Dec 31, 2014 10-K 2017-03-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.